Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 6:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 3,978 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pathophysiology Clear all

Conditions: Mild Cognitive Impairment
Interventions: Water-based Activity + Cognitive Training; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 90 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Olfactory Disorder, Olfaction Disorders, Olfactory Nerve Injuries, Olfactory Nerve Disorder, Olfactory Nerve Diseases, Covid19, Post-Viral Disorder
Interventions: Injection into olfactory cleft; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: San Diego, California • Stanford, California

Conditions: Mild Cognitive Impairment, Diabetes
Interventions: Diabetes Regulation for Eyesight and Memory, Enhanced Usual Care; Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 65 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Disease/Condition Name Cancer-related Cognitive Dysfunction, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions: Not listed
Lead sponsor: University of Rochester NCORP Research Base; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Mobility Limitation, Cognitive Impairment
Interventions: Neurorehabilitation of Standard Walking, Neurorehabilitation of Complex Walking, Sham Transcranial Direct Current Stimulation (Sham tDCS), Active Transcranial Direct Current Stimulation (Active tDCS); Behavioral · Device
Lead sponsor: University of Florida; Other
Eligibility: 65 Years to 110 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Gainesville, Florida

Conditions: Mild Cognitive Impairment, Subjective Cognitive Impairment
Interventions: Ola Mau i ka Hula; Behavioral
Lead sponsor: University of Hawaii; Other
Eligibility: 50 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Honolulu, Hawaii • Wailuku, Hawaii

Conditions: Obesity, Heart Disease, Weight Loss, Diastolic Dysfunction
Interventions: Dietitian counselling; Behavioral
Lead sponsor: Ragavendra Baliga; Other
Eligibility: 21 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Eosinophilic Gastritis, Gastroparesis, Gastric Motility Disorder
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 59 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • Bethesda, Maryland • Salt Lake City, Utah

Conditions: Alzheimer Disease, Dementia, Alzheimer Type
Interventions: E2609, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 21
States / cities: Bellflower, California • Costa Mesa, California • Glendale, California + 18 more

Conditions: NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 169
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 141 more

Conditions: Obesity
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 30 Years
Enrollment: 575 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Encephalomyelitis, Myalgic, Chronic Fatigue Syndrome, Chronic Fatigue Disorder, Chronic Fatigue and Immune Dysfunction Syndrome, Myalgic Encephalomyelitis, Postviral Fatigue Syndrome, Systemic Exertion Intolerance Disease, Infectious Mononucleosis-Like Syndrome, Chronic, Chronic Fatigue-Fibromyalgia Syndrome
Interventions: Bupivacaine Injection; Drug
Lead sponsor: Neuroversion, Inc.; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Anchorage, Alaska

Conditions: Mitral Valve Regurgitation, Left Atrium Dilatation and Hypertrophy, Mitochondrial Dysfunction in the Heart, Cardiomyocyte Apoptosis, Cardiac Inflammation
Interventions: Lovaza group; Drug
Lead sponsor: East Carolina University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: Parkinson's Disease
Interventions: Atomoxetine; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mild Cognitive Impairment, Old Age; Debility
Interventions: Dual task perturbation training; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 55 Years and older
Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Post Operative Delirium, Cognitive Impairment, Vagus Nerve Stimulation, Depression
Interventions: Transcutaneous vagal nerve stimulation, Sham (No Treatment); Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Endometriosis
Interventions: Placebo, OBE2109; Drug
Lead sponsor: ObsEva SA; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 71
States / cities: Chandler, Arizona • Scottsdale, Arizona • Arcadia, California + 59 more

Conditions: Glaucoma
Interventions: Latanoprost, Bimatoprost, Travoprost, Timolol, Dorzolamide, Brinzolamide, Acetazolamide, Methazolamide; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cystic Fibrosis, Ventilatory Defect
Interventions: 19F MRI; Combination Product
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Postoperative Cognitive Dysfunction, Mild Cognitive Impairment
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 65 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Mild Cognitive Impairment, Alzheimer Disease
Interventions: Trier Social Stress Test; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Kidney Injury, Heart; Dysfunction Postoperative, Cardiac Surgery, Children
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 1 Day to 4 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Otitis Media
Interventions: Simethicone, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cognitive Impairment
Interventions: Self-Administered Gerocognitive Examination (SAGE) or Electronic Self-Administered Gerocognitive Examination (eSAGE), Informant Conversation; Other
Lead sponsor: Ohio State University; Other
Eligibility: 65 Years to 89 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Water-based Activity to Enhance Recall in Veterans

Intranasal Injection of PRP Versus Saline for Treatment of Olfactory Dysfunction

Health Beliefs, Glycemic Control, and Preventing Cognitive Decline in African Americans with Diabetes and Mild Cognitive Impairment: a Randomized Clinical Trial

Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

Combining tDCS and Neurorehabilitation to Treat Age-related Deficits of Mobility and Cognition: UPfront Walking Study

Natives Engaged in Alzheimers Research - 'Ike Kupuna

Weight Loss in Pre-Hypertensive Patients With Diastolic Dysfunction

Study of Gastric Motility in Eosinophilic Gastritis

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

STAGES Trial: Study of Adiposity, Growth and Endocrine Stages

Effect of Stellate Ganglion Block on ME/CFS

Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery

Treatment of Executive Dysfunction in Parkinson's Disease

Dual Task Perturbation Training for OAwMCI

Effects of Transcutaneous Vagal Nerve Stimulation on Post-Surgical Return to Consciousness, Delirium, and Depression

A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis

Stop Retinal Ganglion Cell Dysfunction Study

Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis

Postoperative Cognitive Decline, Inflammation, and Plasma Levels of Beta-amyloids

Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease

Near Infrared Spectroscopy for the Detection of Acute Kidney Injury in Children Following Cardiac Surgery

Effect of Simethicone on Eustachian Tube Dysfunction

SAGE for the Early Detection of Cognitive Impairment at Primary Care Provider Visits